Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Malignant Tumors: Mechanistic Insights, Clinical Efficacy, and Emerging Optimization Strategies
DOI:
https://doi.org/10.54097/jdh0fj75Keywords:
Tumor Immunology, CAR-T Immunotherapy, Chimeric Antigen Receptor T Cells, Solid Tumors, Clinical ApplicationAbstract
CAR-T cell therapy has been proven to show favorable efficacy in various hematological malignancies, particularly in acute lymphoblastic leukemia, multiple myeloma, and myelodysplastic syndromes, with promising results also observed in chronic lymphocytic leukemia. Additionally, CAR-T cell therapy can be applied in the treatment of multiple diseases such as hematological tumors and solid tumors, independent of factors including tumor type, patient age, tumor stage, and treatment response. This article outlines the definition, development history, basic principles of CAR-T cell therapy, and its significance in tumor treatment. It further discusses in detail the structure and function of CAR-T cells, their preparation process, clinical applications, safety, and side effects. Finally, the prospects and future directions of CAR-T cell therapy are explored.
Downloads
References
[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA-A Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[2] Dabas P, Danda A. Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy[J]. Medical Oncology, 2023, 40(9): 275.
[3] Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J]. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86(24): 10024-10028.
[4] Mullard A. FDA approves first CAR T therapy[J]. Nature Reviews Drug Discovery, 2017, 16(10): 669. DOI: 10.1038/nrd.2017.191.
[5] [Anonymous]. First-Ever CAR T-cell Therapy Approved in U.S.[J]. Cancer Discovery, 2017, 7(10): OF1. DOI: 10.1158/2159-8290.CD-NB2017-126.
[6] Miliotou A N, Papadopoulou L C. CAR T-cell Therapy: A New Era in Cancer Immunotherapy[J]. Current Pharmaceutical Biotechnology, 2018, 19(1): 5-18.
[7] Dunn G P, Bruce A T, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape[J]. Nature Immunology, 2002, 3(11): 991-998.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

